OKYO Pharma Limited (OKYO) Stock Analysis & Winston Score

OKYO Pharma Limited is a small clinical-stage biotechnology company focused on developing drugs for eye diseases. Its main program targets dry eye disease, a painful condition where the eyes do not produce enough tears, using a drug candidate called OK-101. The company's potential customers are patients and eye care doctors, and it operates in the specialty ophthalmology drug market. OKYO does not yet generate revenue, which explains the 0% margins — it is still running clinical trials and has not sold any approved products. The company is headquartered in the United Kingdom and listed in the United States, keeping a very small footprint typical of early-stage biotechs. The key growth driver is advancing OK-101 through clinical trials toward regulatory approval, but the main risk is that most drug candidates fail before reaching the market, and the company will likely need to raise additional cash to fund ongoing research.